Proalbumin Christchurch, a circulating variant of human serum albumin, is secreted from the liver without cleavage of the hexapeptide situated at the N-terminal end of the peptide chain of proalbumin. We compared ligand-binding properties of proalbumin Christchurch and of normal albumin A from the same individual in order to test the effect of the presence of the hexapeptide. The two albumin forms exhibited similar affinities for palmitate, bilirubin, 8-anilinonaphthalene-1-sulphonate and Bromocresol Green. The patterns of endogenous fatty acids bound to the two forms of albumin were slightly different, although the differences were probably not of physiological significance. From these studies it would appear that the propeptide of proalbumin does not alter the protein conformation in such anions.
A circulating variant of human serum albumin, proalbumin Christchurch, was identified by Brennan & Carrell (1978) in a subject with bisalbuminemia. The variant apparently differs from normal albumin (albumin A) only by the presence of an additional hexapeptide segment, Arg-Gly-Val-Phe-Arg-Gln, at the N-terminal end of the chain. The glutamine residue in the C-terminal position replaces the arginine found in the propeptides of rat proalbumin and bovine proalbumin (Russell & Geller, 1975; Patterson & Geller, 1977) ; thus proalbumin Christchurch lacks a double basic amino acid sequence and is not cleaved before secretion from the liver cell.
The function of the propeptide of proalbumin is not known, but among the suggested roles is that it blocks a binding site for a physiologically important ligand while the albumin is within the liver cell. The proteolytic activity of trypsinogen is blocked in just such a manner by an N-terminal peptide segment (Walsh & Neurath, 1964) . We now report tests of the binding of two important natural ligands, palmitate and bilirubin, and of two additional organic anions to proalbumin Christchurch and to albumin A prepared from a heterozygous individual.
Materials
Proalbumin Christchurch and albumin A were isolated from the serum of a patient with bisalbuminemia as described previously (Brennan & * To whom reprint requests should be addressed. a way as to alter binding sites for organic Carrell, 1978) . A commercial preparation from pooled human plasma was tested for comparison; this was a human albumin fraction V preparation that had been protected against dimerization by blocking the thiol group with half-cystine followed by deionization (from Hyland Diagnostics, Deerfield, IL, U.S.A.
Methods
Palmitate binding was determined by partition of ['4Clpalmitate between heptane and the protein in 0.1 M-NaCl/20 mM-sodium phosphate buffer, pH 7.4, at 370C (Reed et al., 1975a) . Bilirubin binding was measured in the same buffer at 240C by equilibration with bovine albumin-agarose (Reed et al., 1975b) . Spectral changes on binding of bilirubin were measured in an Aminco DW-2A spectrophotometer at 24°C; an appropriate amount of bilirubin freshly dissolved in lOmM-NaOH containing 1 mM-EDTA was added to a 15pM solution of albumin in the saline/phosphate buffer, pH 7.4. Binding of 8-anilinonaphthalene-1-sulphonate and Bromocresol Green was assayed by measuring fluorescence and A630 respectively, as described previously (Reed et al., 1975a on the basis of an a280 value for bovine The optical absorption spectra of bound bilirubin in of 0.661 litre. g-l -cm-l (Doumas, 1975 Fig. 1(a) (Spector, 1975) . The identity of the data for one strong site and one or two somewhat weaker in and proalbumin Christchurch indicates that sites, as has been reported for human albumin incipal binding sites of albumin must be the (Broderson, 1979) .
Yield of colour with Bromocresol Green, probably the most widely used reagent for assay of albumin in serum, was similar with the two albumin species 0 0 (a) from our subject and with the control albumin.
00\
The isolation for control and sample albumins. Table 1 shows the relative composition of the fatty acids extractable from the albumins with (b) heptane. Albumin A and the variant form both contained more myristate and stearate and less oleate and linoleate than did the pooled control 0:Io albumin. On comparison of the two albumin forms isolated from the same subject, proalbumin Christ-* 0 \tOochurch carried less myristate and more stearate than did albumin A. 
Discussion
The present studies show that proalbumin Christchurch binds palmitate, bilirubin and two indicator compounds specific for albumin equally as well as does the normal albumin A isolated from the serum of the same individual. In a separate study, proalbumin isolated from rat liver was found to bind palmitate and bilirubin as well as did rat serum albumin (Peters & Reed, 1980) . Hence the function of the additional hexapeptide in proalbumin will have to be sought elsewhere than in suppression of binding of these ligands.
The differences in fatty acid composition (Table  1 ) between proalbumin Christchurch and albumin A may point to slight differences in relative affinity for different fatty acid species, the variant binding stearate more strongly and myristate less strongly than does the normal form, although both bind palmitate to the same extent. However, the difference is not striking and is probably not of physiological import. The increase in myristate and decrease in stearate in the two albumin forms obtained in New Zealand relative to the control albumin from pooled serum obtained in the U.S.A. would seem to be the result of dietary differences.
One functional defect of proalbumin has been observed. Proalbumin Christchurch and rat proalbumin both fail to bind copper(II) or nickel(II) (Brennan & Carrell, 1979; Peters & Reed, 1980) . This defect was predictable, because the copperbinding site is known to lie at the N-terminus of these albumins and to include the a-amino nitrogen, a site that is blocked in proalbumin. The physiological consequence of this defect is not known.
